multiple system atrophy msa rare neurodegenerative characterized autonomic dysfunction tremors slow movement muscle rigidity postural instability collectively known parkinsonism ataxia caused progressive degeneration neurons several parts brain including basal ganglia inferior olivary nucleus cerebellum many people affected msa experience dysfunction autonomic nervous system commonly manifests orthostatic hypotension impotence loss sweating dry mouth urinary retention incontinence palsy vocal cords important sometimes initial clinical manifestation disorder modified form alphasynuclein protein within affected neurons may cause msa cases occur men affected first showing symptoms age msa often presents symptoms parkinsons disease however msa generally show little response dopamine medications used treat parkinsons disease msa patients tremor exhibit true parkinsonian pillrolling msa distinct multisystem proteinopathy common musclewasting syndrome msa also different multiple organ dysfunction syndrome sometimes referred multiple organ failure multiple organ system failures oftenfatal complication septic shock severe illnesses injuries msa characterized following present variant combined features msa dementia lewy bodies may also existunreliable medical also occasional instances frontotemporal lobar degeneration associated common first sign msa appearance akineticrigid syndrome ie slowness initiation movement resembling parkinsons disease found first presentation common signs onset include problems balance cerebellar ataxia found first presentation followed genitourinary symptoms men women often experience urgency frequency incomplete bladder emptying inability pass urine retention msa patients experience fall first year men first sign erectile dysfunction women also reported reduced genital disease progresses one three groups symptoms predominates arecitation needed one study found correlation deletion genes specific genetic region development msa group japanese patients region question includes gene mice rats appears function nervous system authors study hypothesized may link deletion development followup study unable replicate finding american msa authors us study concluded results indicate gene deletions underlie cases wellcharacterized msa us population contrast japanese experience reported sasaki et al likely reflecting heterogeneity disease different genetic backgroundsclarification needed another study investigated frequency intronic repeat expansions phenomenon implicated canvas disease diagnostic overlap study concluded repeats absent pathologically confirmed msa suggesting alternative genetic multiple system atrophy explained cell loss gliosis proliferation astrocytes damaged areas central nervous system damage forms scar termed glial presence inclusion bodies known bodies movement balance autonomiccontrol centres brain defining histopathologic hallmark major filamentous component papplantos bodies glial neuronal cytoplasmic inclusions mutations substance may play role conformation alphasynuclein different alphasynuclein lewy disease probably starts proposed αsynuclein inclusions found oligodendrocytes result pruning engulfment diseased axonal segments containing aggregated αsynuclein ie lewy neurites tau proteins found glial cytoplasmic inclusion clinical diagnostic criteria defined updated certain signs symptoms msa also occur disorders parkinsons disease making diagnosis mri ct scanning may show decrease size cerebellum pons cerebellar features msac putamen hypointense mri may show increased deposition iron parkinsonian msap form msac hot cross bun sign sometimes found reflects atrophy pontocerebellar tracts give hyper intense signal intensity atrophic mri changes required diagnose disease features often absent especially early course disease additionally changes quite subtle usually missed examiners experienced msacitation needed pathological diagnosis made autopsy finding abundant gcis histological specimens central nervous contrary synucleinopathies develop αsynuclein inclusions primarily neuronal cell msa presents extensive pathological αsynuclein inclusions cytosol oligodendrocytes glial cytoplasmic inclusions limited pathology msa also differs synucleinopathies regional pathological presentation αsynuclein positive inclusions detected predominantly striatum midbrain pons medulla rather brainstem limbic cortical regions typically effected lewy inclusion however recent studies using novel monoclonal antibodies specific cterminally truncated αsynuclein αsynδc shown neuronal αsynuclein pathology abundant previously one group revealed robust αsynuclein pathology pontine nuclei medullary inferior olivary nucleus upon histological analysis neurological tissue msa histopathological investigation six cases pathologically confirmed msa using antibodies directed variety αsynuclein epitopes revealed substantial variation αsynuclein protein deposition across cases brain regions within cases providing evidence strains aggregated conformers may differentially promote pathological prionlike researchers university texas health science center houston concluded protein misfolding cyclic amplification could used distinguish two progressive neurodegenerative diseases parkinson disease multiple system atrophy first process give objective diagnosis multiple system atrophy instead differential msa one several neurodegenerative diseases known synucleinopathies common abnormal accumulation alphasynuclein protein various parts brain synucleinopathies include parkinsons disease lewy body dementias rare historically many terms used refer disorder based predominant systems presented terms discontinued consensus replaced msa awareness older terms definitions helpful understanding relevant literature prior include striatonigral degeneration snd olivopontocerebellar atrophy opca table describing characteristics modern names conditions follows current terminology diagnostic criteria disease established conference experts set forth position second consensus statement defines two categories msa based predominant symptoms disease time evaluation ongoing care neurologist specializing movement disorders recommendedby complex symptoms msa often familiar lessspecialized neurologists hospicehomecare services useful disability progressescitation needed levodopa ldopa drug used treatment parkinsons disease improves parkinsonian symptoms small percentage msa patients recent trial reported msa patients experienced improvement taking levodopa improvement less even improvement transient effect lasting less one year poor response ldopa suggested possible element differential diagnosis msa parkinsons drug riluzole ineffective treating msa management rehabilitation professionals including physiatrists physiotherapists occupational therapists speech therapists others difficulties walkingmovement daily tasks speech problems essentialcitation needed physiotherapists help maintain patients mobility help prevent instructing patients gait training help improve mobility decrease risk physiotherapist may also prescribe mobility aids cane walker increase patients speech therapists may assist assessing treating supporting speech dysarthria swallowing difficulties dysphagia speech changes mean alternative communication may needed example communication aids word chartscitation needed early intervention swallowing difficulties particularly useful allow discussion around tube feeding disease progressioncitation needed point progression disease fluid food modification may implementedcitation needed one particularly serious problem drop blood pressure upon standing risk fainting thus injury falling often responds fludrocortisone synthetic another common drug treatment alphaagonist nondrug treatments include headup tilt elevating head whole bed degrees salt tablets increasing salt diet generous intake fluids pressure elastic stockings avoidance triggers low blood pressure hot weather alcohol dehydration patient taught move transfer sitting standing slowly decrease risk falls limit effect postural instruction ankle pumping helps return blood legs systemic preventative measures raising head bed cm use compression stockings abdominal social workers occupational therapists also help coping disability provision equipment home adaptations services caregivers access healthcare services person msa well family caregiverscitation needed average lifespan onset symptoms patients msa approximately patients require wheelchair within five years onset motor symptoms patients survive beyond disease progresses without remission variable rate present older age parkinsonian features severe autonomic dysfunction poorer predominantly cerebellar features display autonomic dysfunction later better common causes death sudden death death caused infections include urinary catheterization infections feeding tube infections aspiration pneumonia deaths caused cachexia also known wasting multiple system atrophy estimated affect approximately per people autopsy many patients diagnosed life parkinson disease found actually msa suggesting actual incidence msa higher suggest msa affects slightly men women others suggest two sexes equally likely condition commonly presents persons aged mesenchymal stem cell therapy may delay progression neurological deficits patients msacerebellar disease httpsenwikipediaorgwikishydragersyndrome